Physician profile
Danielle Hoffstadt
NPI 1770303349
$565.29
in general payments reported to CMS, 2019-2025
15 companies · $565 in 2025
The $565 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $84.62 | 2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $70.71 | 2025 | Veozah |
| Exact Sciences Corporation | $61.10 | 2025 | The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $52.57 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.93 | 2025 | Jardiance |
| Madrigal Pharmaceuticals | $38.54 | 2025 | Rezdiffra |
| Agios Pharmaceuticals, INC. | $32.32 | 2025 | Pyrukynd |
| Pfizer INC. | $26.21 | 2025 | |
| Ardelyx, INC. | $26.07 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals Lp | $25.96 | 2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $25.85 | 2025 | |
| Medicure Pharma INC. | $20.84 | 2025 | Zypitamag |
| Sanofi-Aventis U.S. LLC | $20.82 | 2025 | |
| Abbvie INC. | $18.74 | 2025 | |
| Lilly USA, LLC | $18.01 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Hoffstadt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.